Copeptin as a Biomarker for Central Diabetes Insipidus Development Following Pituitary Surgery
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Mayo Clinic
- 入组人数
- 199
- 试验地点
- 1
- 主要终点
- Predict lack of central diabetes insipidus development
研究概览
简要总结
- Access the optimal cut point value of copeptin which predicts development of central diabetes insipidus postoperatively with highest accuracy.
- Access the optimal cut point value of copeptin which predicts the lack of central diabetes insipidus postoperatively with highest accuracy
- Access the relative change in copeptin values between baseline and post-surgery as a predictor for diabetes insipidus development.
详细描述
Patient serum levels of copeptin would be measured after phlebotomy of 3 ml of blood in EDTA tube twice a) within 1-4 hours of extubation and b) within 4-24 hours of extubation (the morning following surgery).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 95 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •* Patients with sellar and suprasellar masses who undergo neurosurgical procedure at Mayo Clinic Rochester.
排除标准
- •* Patients with preexisting CDI.
结局指标
主要结局
Predict lack of central diabetes insipidus development
时间窗: 2 years
Using the measured lab value, we will access the optimal cut point value of copeptin which predicts the lack of central diabetes insipidus postoperatively with highest accuracy
Assess relative change
时间窗: 2 years
Using the measured lab value, we will access the relative change in copeptin values between baseline and post-surgery as a predictor for diabetes insipidus development.
Predict central diabetes insipidus development
时间窗: 2 years
Using the measured lab value, we will access the optimal cut point value of copeptin which predicts development of central diabetes insipidus postoperatively with highest accuracy.
次要结局
未报告次要终点
研究者
Dana Erickson
Associate Professor of Medicine
Mayo Clinic